SS18 and synovial sarcoma: Our findings indicate that BET inhibitors may effectively target the intrinsic apoptotic pathway modulated by SS18-SSX in synovial sarcoma, suggesting that BET inhibitors could represent a promising therapeutic approach for this malignancy.